ID   JVE109
AC   CVCL_EG20
SY   JVE-109
DR   ABM; T8225
DR   cancercelllines; CVCL_EG20
DR   DSMZ; ACC-809
DR   DSMZCellDive; ACC-809
DR   GEO; GSM1655602
DR   GEO; GSM1655626
DR   Wikidata; Q54899176
RX   PubMed=26894854;
RX   PubMed=28931069;
CC   Doubling time: ~50 hours (DSMZ=ACC-809).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Colon, hepatic flexure; UBERON=UBERON_0022277.
ST   Source(s): DSMZ=ACC-809; PubMed=26894854
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 9,12
ST   D16S539: 11
ST   D18S51: 11,14
ST   D19S433: 14,16
ST   D21S11: 28
ST   D2S1338: 18
ST   D3S1358: 13,14
ST   D5S818: 11,12
ST   D7S820: 8,9 (DSMZ=ACC-809)
ST   D7S820: 9 (PubMed=26894854)
ST   D8S1179: 12,13
ST   FGA: 20,22
ST   Penta D: 9
ST   Penta E: 16,18
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,22
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   84Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 16
//
RX   PubMed=26894854; DOI=10.18632/oncotarget.7391; PMCID=PMC4924731;
RA   Boot A., van Eendenburg J.D.H., Crobach S., Ruano D., Speetjens F.,
RA   Calame J., Oosting J., Morreau H., van Wezel T.;
RT   "Characterization of novel low passage primary and metastatic
RT   colorectal cancer cell lines.";
RL   Oncotarget 7:14499-14509(2016).
//
RX   PubMed=28931069; DOI=10.1371/journal.pone.0184900; PMCID=PMC5607170;
RA   Boot A., Oosting J., van Eendenburg J.D.H., Kuppen P.J.K., Morreau H.,
RA   van Wezel T.;
RT   "Methylation associated transcriptional repression of ELOVL5 in novel
RT   colorectal cancer cell lines.";
RL   PLoS ONE 12:e0184900.1-e0184900.16(2017).
//